APOTEX CORP. DONATES CRITICAL MEDICINES IN THE FIGHT AGAINST COVID-19
May 26, 2020Responds to Whole-of-America Pandemic Plan
Weston, Florida, May 26th, 2020 – Apotex Corp. announced today that it has donated much needed medicines in the fight against COVID-19 to U.S. Department of Health and Human Services (HHS). The response by Apotex Corp. comes after the Federal Emergency Management Agency issued a general request for information from industry about critical resources.
“Now more than ever, we play a critical role in ensuring patients have access to essential medicines,” said Kiran Krishnan, Senior Vice-President, Global Regulatory Affairs. “For more than 45 years, support for communities in need has been a foundational part of our culture. Given our existing footprint in the US, combined with our portfolio and manufacturing capabilities, we are well-positioned to donate these much-needed medicines to the US Federal Government.”
The donation is close to 300,000 vials of FDA-approved injectable medicines used regularly in treating pneumonia, in patients with COVID-19 in hospital intensive care units (ICU). This equates to more than 35,000 5-day course of treatments. Apotex Corp. was able to make this donation because of continuous assessment regarding product demand, and adjustments to manufacturing and distribution schedules. This approach ensures donations do not impact patients who rely on these essential medicines every day,
Apotex Corp. is a US based company, headquartered in Weston, Florida. It and its global affiliates are leaders in generic pharmaceuticals and biosimilars and are committed to supplying patients with a broad portfolio of high-quality, affordable medicines covering all major therapeutic areas.
-30-
All media inquiries:
Jordan Berman
Vice-President, Global Corporate Affairs
PH: 416-401-7487
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Oct 23, 2025
Apotex Receives Health Canada Approval for LOQTORZI® - The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer
Toronto, ON - October 23, 2025 - Apotex Inc. ("Apotex" or the "Company"), the largest Canadian-based pharmaceutical company, today announced that Health Canada has granted a Notice of Compliance (NOC) for LOQTORZI® (toripalimab) for the treatment of nasopharyngeal carcinoma (NPC), an ultra-rare and aggressive cancer.
-
Oct 8, 2025
Apotex supports launch of home-based cancer care with $1.5M donation
Apotex is helping bring oncology care directly into patients' homes through a $1.5 million donation to Sunnybrook Foundation. The contribution supports the launch of Cancer Care at Home, a new initiative under the Odette Cancer Program that delivers timely cancer care where patients live.
-
Oct 7, 2025
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
Searchlight Pharma Inc.(“Searchlight”), Apotex Inc’s (“Apotex”) Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to linzagolix, a once-daily oral treatment developed by Kissei Pharmaceutical Co., Ltd. Linzagolix belongs to a class of medicines called GnRH antagonists.